Briviact (in Italy: Nubriveo) (brivaracetam)
- Region
- 🇪🇺 EU
- Active substance
- brivaracetam
- Company
- UCB Pharma SA
- Status
- Authorised
- Therapeutic area
- Epilepsy
- EU approval
- Wed 13 Jan 2016
- Application
- EMEA/H/C/003898
- ATC
- N03AX23
- Official record
- www.ema.europa.eu
Indication
Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
Regulatory milestones
No milestones recorded in the last year.
Follow Briviact (in Italy: Nubriveo)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.